Articles related to SURVIVAL OUTCOMES

A patient with advanced, treatment-resistant lung cancer experienced complete tumor disappearance after sodium selenite treatment and remained tumor-free for 10 years. The single case cannot establish efficacy, safety, or causality.

Three-year increases or sustained elevations in NT-proBNP were associated with greater cardiovascular and mortality risks among older adults without prior cardiovascular disease. Participants whose elevations resolved had risks resembling those who remained free of heart stress.

A Veterans Health Administration analysis of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA level below 0.2 ng/mL within 9 months was associated with improved survival. The retrospective findings support a threshold previously identified in clinical trials.

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.

PrimeC lowered neuron-derived TDP-43 levels in a Phase 2b ALS trial, with earlier analyses reporting functional and survival signals requiring confirmation in a planned pivotal study.

A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.